Litigation Details for Acerta Pharma B.V. v. Sandoz Inc. (D. Del. 2022)
Acerta Pharma B.V. v. Sandoz Inc. (D. Del. 2022)
| Docket | ⤷ Start Trial | Date Filed | 2022-02-04 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | |
| Jury Demand | None | Referred To | |
| Patents | 10,167,291; 10,239,883; 10,272,083; 7,459,554; 9,290,504; 9,758,524; 9,796,721 | ||
| Firms | Heyman Enerio Gattuso & Hirzel LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Acerta Pharma B.V. v. Sandoz Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for Acerta Pharma B.V. v. Sandoz Inc. (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-02-04 | External link to document | |||
| 2022-02-03 | 1 | Complaint | #: 2 ’721 patent”); U.S. Patent No. 10,167,291 (“the ’291 patent”); and U.S. Patent No. 10,272,083…to the ’504 patent, the ’524 patent, the ’721 patent, the ’291 patent, and the ’083 patent and was seeking…that the ’504 patent, the ’524 patent, the ’721 patent, the ’291 patent, and the ’083 patent will not be…of U.S. Patent No. 9,290,504 (“the ’504 patent”); U.S. Patent No. 9,758,524 (“the ’524 patent”); U.S.…U.S. Patent No. 10,239,883 (“the ’883 patent”); U.S. Patent No. 9,796,721 (“the | External link to document |
| 2022-02-04 | 4 | Patent/Trademark Report to Commissioner of Patents | ,758,524 ;10,239,883 ;9,796,721 ;10,167,291. (mal) (Entered: 02/07/2022) 4 February 2022 PACER…Acerta Pharma B.V. & AstraZeneca UK Limited 5 10,167,291 1/1/2019 … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,290,504 ;9,758,524…following G Trademarks or G Patents. ( G the patent action involves 35 U.S.C. § 292.): DOCKET…SHARP & DOHME B.V. PATENT OR DATE OF PATENT | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
